Therapeutic Drug Monitoring of Psychotropic Drugs in China: A Nationwide Survey

Objective: To understand the status of therapeutic drug monitoring (TDM) of psychotropic drugs in psychiatric facilities in mainland China and to lay the foundation for improvement of TDM in psychiatry. Methods: A cross-sectional survey was conducted with a locally developed questionnaire among psychiatric facilities in which TDM of psychotropic drugs was available. The questionnaire included laboratory situations, implementation of TDM, equipment and analytical methods, internal quality control (IQC), and external quality assessment (EQA). Results: Forty-seven of the 58 delivered questionnaires were collected from the psychiatric facilities involving 26 provinces in mainland China. The response rate was 81.0%. Among all facilities surveyed, lithium was the most common psychotropic drug (68.1% of the laboratories) monitored by TDM, followed by clozapine (44.7%), carbamazepine (25.5%), chlorpromazine (21.3%), norclozapine (19.1%), risperidone (19.1%), paliperidone (17.0%), valproic acid (14.9%), and quetiapine (10.6%). Only 10.2% of the laboratories had recommendations for dose adjustments based on their TDM reports. Others only provided drug concentration results with no clinical recommendations. The analytical methods used included high-performance liquid chromatography, liquid chromatography with tandem mass spectrometric detection, and immunoassay. For lithium, most hospitals used ion-selective electrode methods. IQC and EQA were still in their infancy. Conclusions: This first nationwide survey showed that TDM has been available in a considerable number of psychiatric hospitals across China. Though current equipment and analytical methods meet the TDM need, much improvement is needed, particularly in new analytical method development, interpretation of results, consultation services, and quality control, including IQC and EQA. Guidance or consensus guideline for TDM of psychotropic drugs in the Chinese language is also urgently required.

[1]  Matthias J. Müller,et al.  AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. , 2014, Pharmacopsychiatry.

[2]  O. Spigset,et al.  Therapeutic drug monitoring (TDM) repertoire in Norway. , 2012, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[3]  Joseph McGraw,et al.  Cytochrome P450 variations in different ethnic populations , 2012, Expert opinion on drug metabolism & toxicology.

[4]  M. Pastore,et al.  Therapeutic Drug Monitoring in Italian Psychiatry , 2011, Pharmacopsychiatry.

[5]  Matthias J. Müller,et al.  AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 , 2011, Pharmacopsychiatry.

[6]  Lewis Couchman,et al.  Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007 , 2010, Therapeutic drug monitoring.

[7]  S. Preskorn Practical Application of Therapeutic Drug Monitoring: A Tale of Two Patients , 2008, Journal of psychiatric practice.

[8]  C. Hiemke Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? , 2008, European Archives of Psychiatry and Clinical Neuroscience.

[9]  Christoph Hiemke,et al.  Clinical utility of drug measurement and pharmacokinetics – therapeutic drug monitoring in psychiatry , 2008, European Journal of Clinical Pharmacology.

[10]  P. Mitchell,et al.  Clozapine in China , 2008, Pharmacopsychiatry.

[11]  M. Saidinejad,et al.  Interference by Carbamazepine and Oxcarbazepine With Serum- and Urine-Screening Assays for Tricyclic Antidepressants , 2007, Pediatrics.

[12]  P. Mitchell,et al.  Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. , 2007, British journal of clinical pharmacology.

[13]  Y. Hekster,et al.  TDM: Therapeutic Drug Measuring or Therapeutic Drug Monitoring? , 2005, Therapeutic drug monitoring.

[14]  T. Lambert,et al.  An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels , 2005, International clinical psychopharmacology.

[15]  R. Morris Delivery of therapeutic drug monitoring services: survey of Australasian clinical pharmacology laboratories. , 1998, Therapeutic drug monitoring.

[16]  R. Morris Australian Cyclosporin Therapeutic Monitoring Method Survey: 1993 , 1994, Therapeutic drug monitoring.

[17]  M. Sampson,et al.  Lithium determinations evaluated in eight analyzers. , 1994, Clinical chemistry.

[18]  S. Preskorn,et al.  Therapeutic drug monitoring. Principles and practice. , 1993, The Psychiatric clinics of North America.

[19]  R. Seifert Therapeutic Drug Monitoring: Psychotropic Drugs , 1989 .

[20]  Brian Whiting,et al.  THERAPEUTIC DRUG MONITORING , 1982, The Lancet.

[21]  H. J. v d. HELM,et al.  The determination of lithium in serum during therapy with lithium salts. , 1961, Clinica chimica acta; international journal of clinical chemistry.

[22]  A. Macgowan,et al.  The use and therapeutic drug monitoring of teicoplanin in the UK. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  W. Fleischhacker,et al.  Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age , 2004, Psychopharmacology.

[24]  P. Mitchell Therapeutic drug monitoring of non-tricyclic antidepressant drugs , 2004, Clinical chemistry and laboratory medicine.